1. In Vivo
  2. >>Archive

Start-Up Previews, November 2015

 
• By Nancy Dvorin

In this month's issue of Start-Up, we profile Botanisol, DynoSense, Moleculera Labs, SPR Therapeutics and TytoCare.

Botanisol LLC applies modern science to known bioactive constituents of plants and aims to develop anti-inflammatories and other novel drugs. Its lead project, TAI-LCx, is a specific anti-inflammatory extract from turmeric essential oil.

The handheld, battery-operated Dyno Sensor from DynoSense Corp. is a health scanner, akin to a digital thermometer, that can...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 
• By Eliza Slawther

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

Sponsored by:

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

Does ReproNovo’s $65m Raise Signal An Oasis In The Fertility Investment Desert?

 
• By Jo Shorthouse

ReproNovo's $65m Series A targets the $1.5bn male infertility market with the first potential oral therapy. Its first-in-class approach to underserved conditions like adenomyosis positions it as an attractive acquisition target in fertility's concentrated market.

Moderna Veteran Launches Icelandic mRNA Firm Despite US Retreat

 
• By David Wild

Axelyf raises $2.6m seed round for lipid nanoparticle delivery platform on heels of end to US federal support for mRNA vaccines.

Podcast: Tevard CEO Sees Hope For His Daughter In Company’s tRNA Platform

 
• By David Wild

Tevard Biosciences CEO Daniel Fischer discusses how engineered suppressor tRNAs overcome nonsense mutations, restoring full-length protein production to treat rare genetic diseases like Dravet syndrome.